XWELL reports FY2022 net loss of $32.8M vs net income of $3.3M prior year; revenue down 24% to $55.9M

XWELL, Inc.

2023-Q1 EPS reported -$0.07 vs consensus -$2.65 ▲ beat (+97.4%)

Total revenue $55.9M in FY2022, down from $73.7M in FY2021; net loss attributable to common shareholders $32.8M vs net income $3.3M.
Loss from operations $31.2M vs income $4.1M; cost of sales up to $43.9M from $41.4M; G&A expenses $31.2M vs $24.2M.
Repurchased ~19.5M shares for $23.8M; 0.8M shares remain under existing buyback program.
Opened 5 XpresSpa at Istanbul Airport; plans Abu Dhabi opening in Q3 2023 and new spa at Philadelphia Airport in 2023.
Expanded CDC biosurveillance partnership with Ginkgo Bioworks to include influenza monitoring; closed underperforming XpresCheck and Treat locations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

XWELL, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

today reported results for the year ended December 31, 2022.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

XWELL, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-046207

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.